Table 1.
Baseline characteristics of the intention to treat population
| RVA (132) | RVS (131) | P-value | Total (263) | |
|---|---|---|---|---|
| Men (%) | 74.2 | 71.0 | 0.582 | 72.6 |
| Age (years) | 63.8 ± 9.5 | 63.1 ± 9.4 | 0.583 | 63.4 ± 9.5 |
| NYHA class II (%) | 6.9 | 7.8 | 0.707 | 7.3 |
| NYHA class III (%) | 88.5 | 88.4 | 88.5 | |
| NYHA class IV ambulatory (%) | 4.6 | 3.9 | 4.2 | |
| Ischaemic cardiomyopathy (%) | 27.3 | 26.0 | 0.889 | 26.6 |
| LVEF (%) | 30.0 ± 7.7 | 29.6 ± 8.1 | 0.858 | 30 ± 8 |
| LVESV (mL) | 154 ± 72 | 157 ± 80 | 0.794 | 155 ± 76 |
| Baseline medication (%) | ||||
| Diuretics (%) | 83.3 | 86.3 | 0.607 | 84.8 |
| ACE inhibitor or ARB (%) | 93.4 | 95.6 | 0.591 | 94.5 |
| Aldosterone antagonist (%) | 33.3 | 37.4 | 0.521 | 35.4 |
| Beta-blocker (%) | 88.6 | 90.1 | 0.842 | 89.4 |
| ICD indication for primary prevention (%) | 98.5 | 97.7 | 0.684 | 98.1 |
| QRS duration (ms) | 161.2 ± 21.4 | 161.0 ± 22.9 | 0.703 | 161.1 ± 22.1 |
| >150 ms (%) | 70.1 | 65.4 | 0.502 | 67.7 |
| LBBB (%) | 81.6 | 80.2 | 0.856 | 80.9 |
| Intrinsic QRS axis (°) | −11 ± 51 | −12 ± 45 | 0.295 | −12 ± 48 |
| RV lead procedural data | ||||
| R wave (mV) | 14.2 ± 6.9 | 13.8 ± 6.8 | 0.581 | 14.0 ± 6.8 |
| RV pacing threshold (V/0.5 ms) | 0.8 ± 0.3 | 0.7 ± 0.3 | 0.12 | 0.8 ± 0.3 |
| RV lead impedance (Ω) | 676.3 ± 146 | 761.5 ± 171.5 | <0.001 | 718.1 ± 164.6 |
| Paced QRS duration (ms) | 140.0 ± 26.0 | 136.6 ± 25.7 | 0.201 | 132 ± 53 |
| Paced QRS axis (°) | 31 ± 136 | 62 ± 103 | 0.06 | 47 ± 121 |
Values are means ± SD, or % unless otherwise indicated. All between-groups differences are statistically non-significant except for RV lead impedance.
NYHA, New York Heart Association; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; LBBB, left bundle block branch.